/Investor DB

Casdin Capital — 2019 Investments

4 investments dated 2019 · listed companies and verified rows first · show all

908 Devices908devices.comin𝕏NASDAQ: MASSJan 2019

908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.

Deep TechDefense TechHardwareMedical DevicesBoston, US

Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)

BoardKevin Hrusovsky(Director)Corey Steffek(Director)

Co-investorsARCH Venture PartnersHercules Capital, Inc.In-Q-TelRazor's Edge VenturesUTECAramco Ventures+5 more

Maze Therapeuticsmazetx.comin𝕏NASDAQ: MAZEFeb 2019

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more

Vividion Therapeuticsvividion.cominApr 2019 · $82Macquired by Bayer

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)inBenjamin F. Cravatt(Scientific Founder)

BoardJohn Park(Executive Officer)

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundAlexandria+4 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Sexton Biotechnologies

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.